mir-192, mir-194 and mir-215: A convergent microrna network suppressing tumor progression in renal cell carcinoma

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2231-2239

  Khella, H W Z ^a,b   Bakhet, M ^a   Allo, G ^b   Jewett, M A S ^c   Girgis, A H ^a   Latif, A ^a   Girgis, H ^a   Von Both, I ^b   Bjarnason, G A ^d   Yousef, G M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 192; MICRORNA 194; MICRORNA 215; NUCLEIC ACID BINDING PROTEIN; PROTEIN MDM2; SMAD1 PROTEIN; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR ZEB2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; PRIORITY JOURNAL; PROTEIN RNA BINDING; PROTEIN TARGETING; TUMOR GROWTH;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HOMEODOMAIN PROTEINS; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84883651195     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt184     Document Type: Article

References (51)

1. Chow, W.H. et al. (2010) Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol., 7, 245-257.
2. Falebita, O.A. et al. (2009) Rising incidence of renal cell carcinoma in Ireland. Int. Urol. Nephrol., 41, 7-12.
3. Chaffer, C.L. et al. (2011) A perspective on cancer cell metastasis. Science, 331, 1559-1564.
4. Zhang, R. et al. (2009) Small but influential: the role of microRNAs on gene regulatory network and 3'UTR evolution. J. Genet. Genomics, 36, 1-6.
5. Sotiropoulou, G. et al. (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA, 15, 1443-1461.
6. White, N.M. et al. (2011) Metastamirs: a stepping stone towards improved cancer management. Nat. Rev. Clin. Oncol., 8, 75-84.
7. Jung, M. et al. (2009) MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med., 13(9B), 3918-3928.
8. White, N.M. et al. (2011) miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J. Urol., 186, 1077-1083.
9. Chow, T.F. et al. (2010) The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J. Urol., 183, 743-751.
10. Lichner, Z. et al. (2012) Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am. J. Pathol., 180, 1675-1687.
11. Redova, M. et al. (2011) MicroRNAs and their target gene networks in renal cell carcinoma. Biochem. Biophys. Res. Commun., 405, 153-156.
12. White, N.M. et al. (2010) MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med., 8, 65.
13. Metias, S.M. et al. (2009) MicroRNAs in clinical oncology: at the crossroads between promises and problems. J. Clin. Pathol., 62, 771-776.
14. White, N.M. et al. (2011) Translating molecular signatures of renal cell carcinoma into clinical practice. J. Urol., 186, 9-11.
15. Heinzelmann, J. et al. (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J. Urol., 29, 367-373.
16. Khella, H.W. et al. (2012) Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol., 33, 131-140.
17. White, N.M. et al. (2011) miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer, 105, 1741-1749.
18. Sun, Y. et al. (2004) Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res., 32, e188.
19. Saal, S. et al. (2009) MicroRNAs and the kidney: coming of age. Curr. Opin. Nephrol. Hypertens., 18, 317-323.
20. Braun, C.J. et al. (2008) p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res., 68, 10094-10104.
21. Pichiorri, F. et al. (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell, 18, 367-381.
22. Dong, P. et al. (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol. Cancer, 10, 99.
23. Wotschofsky, Z. et al. (2011) Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal. Biochem., 417, 233-241.
24. White, N.M. et al. (2010) Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br. J. Cancer, 102, 1244-1253.
25. White, N.M. et al. (2010) Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol. Chem., 391, 411-423.
26. Camp, R.L. et al. (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res., 10, 7252-7259.
27. Curatolo, A. et al. (2007) Molecular characterization of the human common fragile site FRA1H. Genes. Chromosomes Cancer, 46, 487-493.
28. Le, X.F. et al. (2012) Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One, 7, e41170.
29. Meng, Z. et al. (2010) miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology, 52, 2148-2157.
30. Patterson, D.M. et al. (2011) Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis, 14, 255-266.
31. Yang, J.Y. et al. (2006) MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol. Cell Biol., 26, 7269-7282.
32. Polanski, R. et al. (2010) MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism. FEBS Lett., 584, 4695-4702.
33. Wang, T.L. et al. (2004) Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl Acad Sci USA, 101, 3089-3094.
34. Moore, L.E. et al. (2008) Folate metabolism genes, vegetable intake and renal cancer risk in central Europe. Int. J. Cancer, 122, 1710-1715.
35. Mizutani, Y. et al. (2003) Significance of thymidylate synthase activity in renal cell carcinoma. Clin. Cancer Res., 9, 1453-1460.
36. Colavito, D. et al. (2009) Thymidylate synthetase allelic imbalance in clear cell renal carcinoma. Cancer Chemother. Pharmacol., 64, 1195-1200.
37. Boni, V. et al. (2010) miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther., 9, 2265-2275.
38. Wang, J. et al. (2011) Regulatory coordination of clustered microRNAs based on microRNA-transcription factor regulatory network. BMC Syst. Biol., 5, 199.
39. Yuan, X. et al. (2009) Clustered microRNAs' coordination in regulating protein-protein interaction network. BMC Syst. Biol., 3, 65.
40. Bartel, D.P. et al. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
41. Senanayake, U. et al. (2012) miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis, 33, 1014-1021.
42. Krishnamachary, B. et al. (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res., 66, 2725-2731.
43. Bahnassy, A.A. et al. (2012) Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. Exp. Mol. Pathol., 93, 154-161.
44. Haitel, A. et al. (2000) mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res., 6, 1840-1844.
45. Hirata, H. et al. (2007) MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin. Cancer Res., 13, 4123-4129.
46. Noon, A.P. et al. (2010) p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer, 116, 780-790.
47. Noon, A.P. et al. (2012) Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU Int., 109, 1250-1257
48. Miyake, M. et al. (2012) 5-Fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol. Lett., 3, 1195-1202.
49. Hav, M. et al. (2011) MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? Virchows Arch., 458, 197-203.
50. Vatsyayan, R. et al. (2013) Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol. Carcinog., 52, 39-48.
51. Gandellini, P. et al. (2011) MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin. Ther. Targets, 15, 265-279.